CDKN1A

(redirected from CAP20)

CDKN1A

A gene on chromosome 6p21.2 that encodes a cyclin-dependent kinase inhibitor, which binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, thus acting as a regulator of cell cycle progression at G1. CDKN1A expression is controlled by p53, a tumour suppressor that mediates p53-dependent cell cycle G1-phase arrest in response to various stress stimuli. CDKN1A is specifically cleaved by CASP3-like caspases, activating CDK2 and possibly also the apoptosis pathway.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Many other potential adhesins, previously described as upregulated genes in yeast cells derived from models of infection, have been uncovered by a comparative transcriptome analysis of annotated ESTs during in vitro adherence assays to type I collagen and fibronectin, including C-5 sterol desaturase, cap20 protein, high-affinity copper transporter, hexokinase, and transketolase [37,39, 83].
Many reports have shown that the protein p21 (also named WAF1, CAP20. Cip1, or Sdi 1) is the founding member of the Cip/Kip family of cyclin-dependent kinase inhibitors, which also includes p27 (el-Deiry et al.